The occurrence of refractoriness and mast cell mediator release following mannitol-induced bronchoconstriction.
For several hours after exercise-induced bronchoconstriction, there is diminished responsiveness to repeated challenge. The mechanism causing this refractoriness is unclear. Inhalation of dry powder mannitol is a new bronchial provocation test that has been suggested as a surrogate for an exercise challenge. Refractoriness to repeated mannitol challenge has however not been established. Our objective was to investigate if repeated challenge with mannitol is associated with refractoriness and diminished release of mast cell mediators of bronchoconstriction. Sixteen subjects with asthma underwent repeated inhalation of mannitol 90 min apart. Lung function was assessed by forced expiratory volume in 1 s (FEV₁). The urinary excretion (ng/mmol creatinine) of the mediators 9α,11β-prostaglandin (PG) F₂ and leukotriene (LT) E₄ were measured. The group mean fall in FEV₁ after the second challenge was 48.5 ± 5.8% of the first (P < 0.001). The protection afforded by the initial challenge, however, varied considerably between subjects (range 88-0%). Furthermore, the urinary excretion of the two mediators was increased after both challenges. The average excretion of mediators after the challenges was significantly higher for the six most refractory subjects. This was observed both for LTE₄ (95.6 ± 5.2 vs. 58.0 ± 2.4 for the 6 least refractory) (P < 0.001) and for 9α,11β-PGF₂ (137.6 ± 6.7 vs. 50.1 ± 1.1 for the 6 least refractory) (P = 0.002). As occurs with exercise-induced bronchoconstriction, repeated inhalation of mannitol induced refractoriness. We propose that refractoriness is due to tachyphylaxis at the level of the airway smooth muscle responsiveness to mediators of bronchoconstriction rather than due to fatigue of their release from mast cells.
The Unit for Experimental Asthma and Allergy Research, Division of Physiology, The National Institute of EnvironmentalMedicine, Sweden. johan.larsson@ki.se
Johan
J
Larsson
Clare P
CP
Perry
Sandra D
SD
Anderson
John D
JD
Brannan
Sven-Erik
SE
Dahlén
Barbro
B
Dahlén
D000280:Administration, Inhalation; D000328:Adult; D001249:Asthma / Q000276:immunology / Q000503:physiopathology* / Q000652:urine; D016084:Bronchoconstriction / Q000187:drug effects / Q000276:immunology*; D015237:Dinoprost / Q000652:urine; D015444:Exercise; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D017999:Leukotriene E4 / Q000652:urine; D008297:Male; D008353:Mannitol / Q000008:administration & dosage*; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology*
D008353:Mannitol; D017999:Leukotriene E4; D015237:Dinoprost